课题基金 / 基金详情

Regulation of Keratinocyte Survival and Death

Regulation of Keratinocyte Survival and Death
角质形成细胞存活和死亡的调节
批准号:
6477933
负责人:
ULRICH RODECK
金额:
$27.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2007-02-28

项目摘要

项目成果

ULRICH RODECK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Aberrant signaling through the epidermal growth factor receptor (EGFR/erbB 1) is frequently observed in epithelial malignancies. However, it is poorly understood which of the manifold effects of EGFR activation are critical to the malignant phenotype. During the previous grant cycle the applicants have assigned a novel role to the EGFR in support of anchorage-independent epithelial cell survival. Among the many functions of the EGFR this effect is considered to be rate-limiting to the development of advanced epithelial malignancies as it is likely to impair the establishment of metastatic lesions. The overall goal of this application is to define molecular mechanisms and pathways by which EGFR activation controls anchorage-independent epithelial cell survival. Preliminary results by the applicants demonstrate that matrix-independent, EGFR-dependent MEK/MAPK signaling is critically required for this process. Further preliminary results suggest that (i) EGFR activation sustains MAPK activation of suspended keratinocytes, at least in part, by suppressing MAPK phosphatases; (ii) posttranslational modifications of apoptosis regulators through MAPK are likely to contribute to keratinocyte survival in this setting; (iii) MAPK-dependent effects on transcription of apoptosis modifiers further enhances the survival phenotype. These preliminary results provide the basis for three specific aims focusing on EGFR-dependent regulation of MAPK activity and molecular consequences of sustained MAPK signaling as they relate to keratinocyte survival. The hypotheses to be tested are (1) EGFR activation is required to suppress MAPK phosphatases and thus enables sustained MAPK signaling in suspension culture; (2) MAPK-dependent activation of Rsks contributes to posttranslational modifications of Bcl-2 family members and thus supports cell survival; (3) EGFR-dependent MAPK activation in suspension culture further supports cell survival by maintaining transcription of anti-apoptotic genes. The proposed studies are relevant to physiological states and pathological conditions in which epithelial cells need to survive in the absence of optimal matrix interaction ranging from wound healing to neoplasia. Furthermore, they will provide valuable information about EGFR-dependent control of apoptosis susceptibility as it relates to targeting the EGFR in epithelial cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Monoclonal Antibody-based Prodrugs - Novel Tools for Cancer Therapy
  • 批准号:
    8013862
  • 项目类别:
  • 资助金额:
    $16.9万
  • 财政年份:
    2010
  • 负责人:
    ULRICH RODECK
  • 依托单位:
Monoclonal Antibody-based Prodrugs - Novel Tools for Cancer Therapy
  • 批准号:
    7788327
  • 项目类别:
  • 资助金额:
    $22.28万
  • 财政年份:
    2010
  • 负责人:
    ULRICH RODECK
  • 依托单位:
REGULATION OF KERATINOCYTE SURVIVAL
  • 批准号:
    6478028
  • 项目类别:
  • 资助金额:
    $4.37万
  • 财政年份:
    2001
  • 负责人:
    ULRICH RODECK
  • 依托单位:
TRANSFORMING GROWTH FACTOR-B EXPRESSION IN MELANOMA DEVELOPMENT AND PROGRESSION
  • 批准号:
    6269086
  • 项目类别:
  • 资助金额:
    $14.65万
  • 财政年份:
    1998
  • 负责人:
    ULRICH RODECK
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: